Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Kalow

Showing results (51-60 of 188) with videos related to

Pageof 19
Sort By:
Clinical Pharmacology and Therapeutics|May 1, 1993
The use of caffeine for enzyme assays: a critical appraisalW Kalow, B K Tang
Clinical Pharmacology and Therapeutics|July 1, 1993
Thiopurine S-methyltransferase activity in a Chinese populationE J Lee, W Kalow
Lancet (London, England)|August 18, 1973
Drugs causing rigidity in malignant hyperthermiaW Kalow, B A Britt
Clinical Pharmacology and Therapeutics|January 1, 1991
Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smokingW Kalow, B K Tang
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1985
Mephenytoin hydroxylase activity in human liver: inhibition by steroidsM Jurima, T Inaba, W Kalow
Pharmacology|May 15, 1999
Repeat administration of drugs as a means to assess the genetic component in pharmacological variabilityW Kalow, L Endrenyi, B Tang
Clinical Pharmacology and Therapeutics|March 1, 1984
Sparteine oxidation by the human liver: absence of inhibition by mephenytoinM Jurima, T Inaba, W Kalow
American Journal of Human Genetics|May 1, 1986
Family studies of mephenytoin hydroxylation deficiencyT Inaba, M Jurima, W Kalow
Life Sciences|June 9, 1980
Antipyrine metabolism in the rat by three hepatic monooxygenasesT Inaba, M Lucassen, W Kalow
European Journal of Clinical Pharmacology|January 1, 1993
Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6)J Pressacco, R Muller, W Kalow
Pageof 19

Showing results (51-60 of 188) with videos related to

Sort By:
Pageof 19
Clinical Pharmacology and Therapeutics|May 1, 1993
The use of caffeine for enzyme assays: a critical appraisalW Kalow, B K Tang
Clinical Pharmacology and Therapeutics|July 1, 1993
Thiopurine S-methyltransferase activity in a Chinese populationE J Lee, W Kalow
Lancet (London, England)|August 18, 1973
Drugs causing rigidity in malignant hyperthermiaW Kalow, B A Britt
Clinical Pharmacology and Therapeutics|January 1, 1991
Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smokingW Kalow, B K Tang
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1985
Mephenytoin hydroxylase activity in human liver: inhibition by steroidsM Jurima, T Inaba, W Kalow
Pharmacology|May 15, 1999
Repeat administration of drugs as a means to assess the genetic component in pharmacological variabilityW Kalow, L Endrenyi, B Tang
Clinical Pharmacology and Therapeutics|March 1, 1984
Sparteine oxidation by the human liver: absence of inhibition by mephenytoinM Jurima, T Inaba, W Kalow
American Journal of Human Genetics|May 1, 1986
Family studies of mephenytoin hydroxylation deficiencyT Inaba, M Jurima, W Kalow
Life Sciences|June 9, 1980
Antipyrine metabolism in the rat by three hepatic monooxygenasesT Inaba, M Lucassen, W Kalow
European Journal of Clinical Pharmacology|January 1, 1993
Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6)J Pressacco, R Muller, W Kalow
Pageof 19